Lebrikizumab (IL-13 Inhibitor)
Moderate-to-Severe Atopic Dermatitis
Sponsor Eli Lilly
800 Enrollment Target
150 Trial Sites
5 Countries
December 2028 Est. Completion
About This Trial
Real-world effectiveness study in diverse patient population.
Primary Endpoints
- IGA 0/1 response
- EASI-75 achievement
Latest Update
January 2026
Approved in EU and US. Real-world data confirms efficacy with convenient monthly dosing.